Denali Therapeutics shares are trading shares are trading higher after the FDA selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics Pilot Program.
Portfolio Pulse from Benzinga Newsdesk
Denali Therapeutics shares are trading higher after the FDA selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics Pilot Program.
June 03, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Denali Therapeutics shares are trading higher following the FDA's selection of DNL126 for the Support for clinical Trials Advancing Rare disease Therapeutics Pilot Program.
The FDA's selection of DNL126 for the pilot program is a significant regulatory milestone, likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100